Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the
second most common form of acute leukemia in children. Despite this, very little …
second most common form of acute leukemia in children. Despite this, very little …
BCL2 and MCL1 inhibitors for hematologic malignancies
BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …
hematologic cancers and play important roles in their biology either through dysregulation or …
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Effective treatment options are limited for patients with acute myeloid leukemia (AML) who
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …
Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study
PURPOSE Effective treatment options are limited for patients with acute myeloid leukemia
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing
induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and …
induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and …
BH3-mimetic drugs: blazing the trail for new cancer medicines
Defects in apoptotic cell death can promote cancer and impair responses of malignant cells
to anti-cancer therapy. Pro-survival BCL-2 proteins prevent apoptosis by kee** the cell …
to anti-cancer therapy. Pro-survival BCL-2 proteins prevent apoptosis by kee** the cell …
Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive …
PURPOSE The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in
acute myeloid leukemia (AML), with promising response rates in combination with …
acute myeloid leukemia (AML), with promising response rates in combination with …
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies
The B cell leukemia/lymphoma 2 (BCL-2) inhibitor venetoclax is effective in chronic
lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid …
lymphocytic leukemia (CLL); however, resistance may develop over time. Other lymphoid …
[HTML][HTML] Venetoclax resistance: mechanistic insights and future strategies
Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …
Venetoclax for AML: changing the treatment paradigm
Venetoclax is a specific B-cell lymphoma-2 (BCL-2) inhibitor that can restore activation of
apoptosis in malignancies, the survival of which depends on dysregulation of this pathway …
apoptosis in malignancies, the survival of which depends on dysregulation of this pathway …